NRSN
NeuroSense Therapeutics Ltd.$0.79
LiveJun 22, 2026
Market cap
$19.46M
52w range
0.63 – 2.35
P / E
—
EPS
—
Volume
321.11K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on NeuroSense Therapeutics Ltd.’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
Valuation multiples
Price- and EV-based multiples plus shareholder yields. Snapshot at each fiscal year-end from key_metrics (FMP).
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Headline | ||||
| Market cap | — | — | — | — |
| Enterprise value | — | — | — | — |
| Multiples | ||||
| P / E | — | — | — | — |
| P / B | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / Sales | — | — | — | — |
| EV / FCF | — | — | — | — |
| Yields | ||||
| Earnings yield | — | — | — | — |
| Free cash flow yield | — | — | — | — |
| Dividend yield | — | — | — | — |
Profitability
Margin structure across the last 5 fiscal years
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Margins | ||||
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| EBITDA margin | — | — | — | — |
| EBIT margin | — | — | — | — |
| Pre-tax margin | — | — | — | — |
| Net margin | — | — | — | — |
| Cost structure | ||||
| Cost of revenue / sales | — | — | — | — |
| R&D intensity | — | — | — | — |
| SG&A intensity | — | — | — | — |
| Effective tax rate | — | — | — | — |
Returns on capital
ROE / ROA / ROC / ROIC over the relevant capital base, plus the 3-step DuPont decomposition of ROE.
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Returns | ||||
| Return on equity (ROE) | — | — | — | — |
| Return on assets (ROA) | — | — | — | — |
| Return on capital (ROC) | — | — | — | — |
| Return on invested capital (ROIC) | — | — | — | — |
| Asset turnover | — | — | — | — |
| DuPont · ROE decomposition | ||||
| Net margin | — | — | — | — |
| Asset turnover (× revenue / assets) | — | — | — | — |
| Equity multiplier (× assets / equity) | — | — | — | — |
Activity & efficiency
Turnover ratios and days-outstanding — how efficiently the business converts assets and working capital into sales and cash.
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Turnover | ||||
| Asset turnover | — | — | — | — |
| Fixed-asset turnover | — | — | — | — |
| Inventory turnover | — | — | — | — |
| Receivables turnover | — | — | — | — |
| Payables turnover | — | — | — | — |
| Days outstanding | ||||
| Days sales outstanding (DSO) | — | — | — | — |
| Days inventory outstanding (DIO) | — | — | — | — |
| Days payables outstanding (DPO) | — | — | — | — |
| Cash conversion cycle | — | — | — | — |
Cash flow quality
How well reported earnings translate into operating and free cash flow, plus reinvestment intensity.
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Operating CF / Net income | — | — | — | — |
| FCF / Net income | — | — | — | — |
| FCF margin | — | — | — | — |
| OCF margin | — | — | — | — |
| CapEx / Revenue | — | — | — | — |
| CapEx / D&A | — | — | — | — |
| Stock-based comp / Revenue | — | — | — | — |
Per-share & shareholder yield
EPS, book value, sales, cash flow and dividends per share — plus payout / retention.
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| EPS · diluted | -0.39 | -0.82 | -0.26 | 1.65 |
| EPS · basic | — | — | — | — |
| Book value / share | — | — | — | — |
| Tangible BV / share | — | — | — | — |
| Sales / share | — | — | — | — |
| Operating CF / share | — | — | — | — |
| Free cash flow / share | — | — | — | — |
| Dividends / share | — | — | — | — |
| Payout ratio | — | — | — | — |
| Retention ratio | — | — | — | — |
Growth
Year-over-year change for headline P&L lines, plus through-cycle CAGR
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E | 3y CAGR |
|---|---|---|---|---|---|
| Top-line | |||||
| Revenue · YoY | — | +359.05% | +308.04% | +2593.10% | +696.05% |
| Gross profit · YoY | — | — | — | — | — |
| Profit | |||||
| Operating income · YoY | — | — | — | — | — |
| EBITDA · YoY | — | — | — | — | — |
| Net income · YoY | — | — | — | — | — |
| Operating | |||||
| EBIT · YoY | — | — | — | — | — |
| R&D · YoY | — | — | — | — | — |
| Per-share | |||||
| EPS · diluted · YoY | — | -112.99% | +67.77% | +724.29% | — |
| EPS · basic · YoY | — | — | — | — | — |
Credit & leverage
Balance-sheet health + interest coverage + liquidity. Coverage ratios use period-end debt and trailing interest expense.
ActualEstimate
| In USD | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|
| Leverage | ||||
| Total debt | — | — | — | — |
| Net debt | — | — | — | — |
| Net debt / EBITDA | — | — | — | — |
| Debt / equity | — | — | — | — |
| Debt / assets | — | — | — | — |
| Equity / assets | — | — | — | — |
| Coverage | ||||
| EBITDA / interest expense | — | — | — | — |
| Operating income / interest | — | — | — | — |
| Interest expense | — | — | — | — |
| Liquidity | ||||
| Current ratio | — | — | — | — |
| Quick ratio | — | — | — | — |
| Cash ratio | — | — | — | — |
| Working capital | — | — | — | — |
| Working capital / revenue | — | — | — | — |
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
Valuation
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| P / E | — | — |
| P / B | — | — |
| EV / EBITDA | — | — |
| EV / Sales | 0.00x | 0.00x |
| Earnings yield | -56.8% | -45.7% |
| FCF yield | -39.2% | -45.4% |
Returns
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| ROE | 713.1% | -395.3% |
| ROA | -1082.2% | -223.2% |
| ROIC | 797.5% | -372.8% |
Leverage & liquidity
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Debt / equity | — | — |
| Net debt / EBITDA | -0.00 | 0.33 |
| Interest coverage | — | — |
| Current ratio | 0.31x | 2.21x |
| Quick ratio | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).